This has been reflected in our 2023 annual guidance range. Moving to gross margin. We expect our gross margin percentage to trend lower from where we exited the year, as newly introduced products expand and become a large percentage of overall revenue. This is particularly the case for the Xenium instrument, as this is currently a low-margin instrument. The impact on overall company gross margin will be greater as more instruments are placed. We plan to continue to invest across the business to support our growth. And while our rate of headcount growth in 2023 will be lower than in 2022, we will still be adding additional headcount, mainly to support new product development and support. As our new operations facility in Pleasanton nears completion, we expect a significant reduction in capital expenses in the back half of this year and will continue to drive towards becoming free cash flow positive by the end of 2023.